Selpercatinib (2) (Retsevmo®) – Medullary thyroid carcinoma (MTC), RET-mutated, after cabozantinib and/or vandetanib prior therapy, ≥ 12 years

1. Characteristics

Start date 15.03.2021
Resolution 02.09.2021
INN Selpercatinib
Brand name Retsevmo®
Company Lilly Deutschland GmbH
G-BA procedure ID 2021-03-15-D-656
ATC code L01EX22
ICD-10 codes C73Malignant neoplasm of thyroid gland
Therapeutic area Oncological diseases
Reason for procedure New indication
Regulatory status Conditional Approval
Specialties Bundling ACT change

Indication (German)

Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib.

Subgroup Indication Comparator
Erwachsene und Jugendliche ab 12 Jahren mit einem fortgeschrittenen medullären Schilddrüsenkarzinom (MTC); mit RET Rezeptor-Tyrosinkinase (rearranged during transfection - RET) Mutation, bei denen eine systemische Therapie angezeigt ist; nach vorangegangener Therapie mit Cabozantinib und/ oder Vandetanib Patientenindividuelle Therapie unter Auswahl von - Cabozantinib, - Vandetanib und - Best-Supportive-Care unter Berücksichtigung der Vortherapie und des Allgemeinzustandes

9. Associated procedures

Resolution INN Brand name Indication Additional benefit
Selpercatinib (3) Retsevmo® Thyroid carcinoma (MTC), RET fusion+, after sorafenib and/or lenvatinib pre-therapy
Selpercatinib (2) Retsevmo® Medullary thyroid carcinoma (MTC), RET-mutated, after cabozantinib and/or vandetanib prior therapy, ≥ 12 years
Selpercatinib Retsevmo® Non-small cell lung carcinoma (NSCLC), RET fusion+, after platinum-based chemotherapy and/or immunotherapy


<< List of all resolutions